Regulus Therapeutics (RGLS) Fails to deliver data

Key failure to deliver metrics for Regulus Therapeutics:

• Last SEC data release: 2025-11-14
• Last 15 days FTD volume: N/A
• Last 3 months FTD volume: N/A
• Last 12 months FTD volume: A$5.6 M

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Regulus Therapeutics (RGLS) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Regulus Therapeutics (RGLS) - since 2022

Regulus Therapeutics (RGLS) Failure to deliver volume, Year over Year

FTD volume in the last 3 months for similar companies or competitors

Company	FTD volume (3 months)	FTD volume (1 year)	Country
GlaxoSmithKline GSK	A$72.01 M	A$0.40 B	🇬🇧 UK
Sanofi SNY	A$4.1 M	A$62.72 M	🇫🇷 France
Biogen BIIB	A$22.86 M	A$94.5 M	🇺🇸 USA
AstraZeneca AZN	A$21.14 M	A$0.11 B	🇬🇧 UK
Alnylam Pharmaceuticals ALNY	A$13.72 M	A$39.91 M	🇺🇸 USA
Sangamo Therapeutics SGMO	A$0.58 M	A$9.74 M	🇺🇸 USA
Bristol-Myers Squibb BMY	A$6.09 M	A$0.21 B	🇺🇸 USA